Membrane-bound/soluble IL-2 receptor (IL-2R) and levels of IL-1 alpha, IL-2, and IL-6 in the serum and in the PBMC culture supernatants from 17 patients with hematological malignancies
- PMID: 7493395
- DOI: 10.1007/BF02822523
Membrane-bound/soluble IL-2 receptor (IL-2R) and levels of IL-1 alpha, IL-2, and IL-6 in the serum and in the PBMC culture supernatants from 17 patients with hematological malignancies
Abstract
The present study investigated the peripheral blood mononuclear cells (PBMC) blastic responses to PHA, PHA plus recombinant IL-2 (rIL-2) and rIL-2 alone; the expression of membrane-bound IL-2R on PHA-stimulated PBMC; and the levels of IL-1 alpha, IL-2, IL-6, and sIL-2R in serum and in culture supernatants from PHA-stimulated PBMC in 17 patients with with non-Hodgkin's lymphoma (NHL), 4 with Hodgkin's lymphoma (HL), 5 with Hairy cell leukemia, 1 with chronic myelogenous leukemia, and 1 with chronic lymphocytic leukemia. The patients with HL and NHL with active disease (AD) were separated from those in clinical remission. The patients with AD were studied at diagnosis (obviously before therapy) and the patients in clinical remission were out of therapy since at least 6 mo. The lymphocyte blastogenic response to PHA was significantly lower in patients with HL and NHL with AD than in the control group. The response to rIL-2 alone was in the same range in the control group and in HL and NHL AD patients. By adding rIL-2 to PHA there was an increase of the blastogenic response of the same patients. The percentage of CD25 expressed on PHA-stimulated lymphocytes from patients with HL and NHL AD and from normal subjects is in the same range. Serum levels of IL-2, IL-6, and sIL-2R were significantly higher in HL and NHL AD patients than in controls as well as in all other hematological malignancies. Supernatants derived from PHA-stimulated PBMC were assessed for the presence of cytokines and sIL-2R by ELISA. The levels of IL-2, IL-6, and sIL-2R were significantly lower in HL and NHL AD patients than in controls as well as in all other hematological malignancies.
Similar articles
-
Membrane-bound and soluble IL-2 receptors (p55 and p75 chains) on peripheral blood mononuclear cells from patients with solid malignancies.Cell Biophys. 1993 Jan-Jun;22(1-3):79-99. doi: 10.1007/BF03033868. Cell Biophys. 1993. PMID: 7889544
-
Release of sIL-2R alpha from and activation of native human peripheral blood mononuclear cells by recombinant IL-15.Clin Immunol Immunopathol. 1996 Jul;80(1):67-75. doi: 10.1006/clin.1996.0095. Clin Immunol Immunopathol. 1996. PMID: 8674241
-
Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients.Eur J Cancer. 1997 Apr;33(4):602-7. doi: 10.1016/s0959-8049(96)00486-8. Eur J Cancer. 1997. PMID: 9274442
-
The role of tumor-associated macrophages on serum soluble IL-2R levels in B-cell lymphomas.J Clin Exp Hematop. 2014;54(1):49-57. doi: 10.3960/jslrt.54.49. J Clin Exp Hematop. 2014. PMID: 24942946 Review.
-
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.Eur J Cancer. 1997 Jan;33 Suppl 1:S34-6. doi: 10.1016/s0959-8049(96)00327-9. Eur J Cancer. 1997. PMID: 9166099 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical